Biotech

The Readout LOUD

Listen: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

FDA on Novartis data manipulation controversy: ‘We happened to be lucky’

By Matthew Herper

Adam's Take

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By Adam Feuerstein

Biotech

Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal

By Matthew Herper

Biotech

Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy

By Adam Feuerstein

Adam's Take

This troubled biotech needed cash, so it turned to a predatory lender: its own CEO

By Adam Feuerstein

Biotech

A writer shared her story about getting frightening genetic results online. The response was surprising

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Biotech

Is Roche starting a price war in cancer? Maybe not

By Matthew Herper

Biotech

How Amgen plans to BiTE into CAR-T’s hype

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Biotech

Can targeting one protein complex solve multiple diseases? NodThera is betting on it

By Diana Cai

Biotech

Roche drug approval offers a glimpse at the future of cancer treatment

By Matthew Herper

The Readout LOUD

Listen: The serious side of spit kits, how BiTEs leave a mark, & Sarepta’s sluggish study

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Something Ventured

Compass Therapeutics and these three other biotech startups got venture funding a year ago. Where are they now?

By Kate Sheridan

Biotech

As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

By Adam Feuerstein

Biotech

Novartis ousted top scientists over manipulation of data for gene therapy

By Damian Garde and Matthew Herper

Biotech

Regeneron drug proves effective in genetic form of high cholesterol

By Matthew Herper and Damian Garde

Biotech

Vertex, known for cystic fibrosis drugs, sets its sights on taming pain

By Jonathan Saltzman — Boston Globe

Biotech

An old idea that’s gaining new traction: curing Alzheimer’s by targeting gum-disease bacteria

By Sharon Begley

Biotech

Toddler denied $2.1m gene therapy will now get it for free

By Jonathan Saltzman — Boston Globe

Adam's Take

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

By Adam Feuerstein

Biotech

Biotech faces a crisis in credibility fueled by boom-era hubris

By Matthew Herper

Senator Elizabeth Warren (D-MA) (L), Senator Bernie Sanders (I-VT) (2L), Senate Minority Leader Chuck Schumer (D-NY) (3L), Senator Tammy Baldwin (D-WI)

Politics

Senators blast Novartis over data manipulation before approval of Zolgensma

By Nicholas Florko

Pharmalot

Pharmalittle: Delayed approval decision raises fears for Vascepa; drug prices snakebit by lack of competition

By Elizabeth Cooney

Biotech

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

By Adam Feuerstein

The Readout LOUD

Listen: Novartis and the no good, very bad week

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech industry aims to spark girls’ interests in science long before high school

Vertex sinks on reports of deaths of patients taking cystic fibrosis drug

Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

Listen: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

FDA on Novartis data manipulation controversy: ‘We happened to be lucky’

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal

Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy

This troubled biotech needed cash, so it turned to a predatory lender: its own CEO

A writer shared her story about getting frightening genetic results online. The response was surprising

Is Roche starting a price war in cancer? Maybe not

How Amgen plans to BiTE into CAR-T’s hype

Can targeting one protein complex solve multiple diseases? NodThera is betting on it

Roche drug approval offers a glimpse at the future of cancer treatment

Listen: The serious side of spit kits, how BiTEs leave a mark, & Sarepta’s sluggish study

Compass Therapeutics and these three other biotech startups got venture funding a year ago. Where are they now?

As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

Novartis ousted top scientists over manipulation of data for gene therapy

Regeneron drug proves effective in genetic form of high cholesterol

Vertex, known for cystic fibrosis drugs, sets its sights on taming pain

An old idea that’s gaining new traction: curing Alzheimer’s by targeting gum-disease bacteria

Toddler denied $2.1m gene therapy will now get it for free

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

Biotech faces a crisis in credibility fueled by boom-era hubris

Senators blast Novartis over data manipulation before approval of Zolgensma

Pharmalittle: Delayed approval decision raises fears for Vascepa; drug prices snakebit by lack of competition

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

Listen: Novartis and the no good, very bad week